Former top Rockies prospects find the road back

1 Comment

In 2010, Baseball America rated Rockies left-handers Tyler Matzek and Christian Friedrich the 23rd and 33rd best prospects in the game, respectively. They were eighth and 12th among pitchers. However, the stock of both had plummeted in the two years since, even though neither suffered a major injury. Neither came close to sniffing the top 100 this year. BA ranked them 12th and 14th, respectively, on a Rockies list that placed four players in the top 100.

Fortunately, two two are off to great starts in reviving their prospecthood. Matzek has a 1.72 ERA and a 19/8 K/BB ratio in 15 2/3 innings for high-A Modesto. Friedrich has a 2.33 ERA and an 18/3 K/BB ratio in 19 1/3 innings for Triple-A Colorado Springs.

In both cases it may be too early to get too excited. Still, the Rockies couldn’t have hoped for much more. Matzek had a 9.82 ERA and more walks (46) than strikeouts (37) in his 10 starts for Modesto last year before being demoted to low-A ball. He wasn’t any good there either, finishing with a 4.36 ERA and a 74/50 K/BB ratio in 64 innings. Friedrich ended up with ERAs of 5.05 and 5.00 in his two years at Double-A Tulsa. He went from averaging 12.0 K/9 IP in 2009 to 8.0 in 2010 and 7.0 last year.

Matzek still has a long way to go before he reaches the majors, but Friedrich might help this year if he keeps it up. Having made deals for Drew Pomeranz, Alex White and Tyler Chatwood over the last year, the Rockies may suddenly find themselves with an excess of young pitching to make available in future trade talks.

MLB, union resume blood testing after pandemic, lockout

Scott Taetsch-USA TODAY Sports
1 Comment

NEW YORK – In the first acknowledgment that MLB and the players’ association resumed blood testing for human growth hormone, the organizations said none of the 1,027 samples taken during the 2022 season tested positive.

HGH testing stopped in 2021 because of the COVID-19 pandemic. Testing also was halted during the 99-day lockout that ended in mid-March, and there were supply chain issues due to COVID-19 and additional caution in testing due to coronavirus protocols.

The annual public report is issued by Thomas M. Martin, independent program administrator of MLB’s joint drug prevention and treatment program. In an announcement accompanying Thursday’s report, MLB and the union said test processing is moving form the INRS Laboratory in Quebec, Canada, to the UCLA Laboratory in California.

MLB tests for HGH using dried blood spot testing, which was a change that was agreed to during bargaining last winter. There were far fewer samples taken in 2022 compared to 2019, when there were 2,287 samples were collected – none positive.

Beyond HGH testing, 9,011 urine samples were collected in the year ending with the 2022 World Series, up from 8,436 in the previous year but down from 9,332 in 2019. And therapeutic use exemptions for attention deficit hyperactivity disorder dropped for the ninth straight year, with just 72 exemptions in 2022.

Overall, the league issued six suspensions in 2022 for performance-enhancing substances: three for Boldenone (outfielder/first baseman Danny Santana, pitcher Richard Rodriguez and infielder Jose Rondon, all free agents, for 80 games apiece); one each for Clomiphene (Milwaukee catcher Pedro Severino for 80 games), Clostebol (San Diego shortstop Fernando Tatis Jr. for 80 games) and Stanozolol (Milwaukee pitcher J.C. Mejia for 80 games).

There was an additional positive test for the banned stimulant Clobenzorex. A first positive test for a banned stimulant results in follow-up testing with no suspension.